Clinical Trials Browser

Recruiting × camrelizumab × Other hematologic neoplasm × Clear all

NCT05772273 2025-11-21

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma